TruScreen Rights Offer closes

NZX/ASX Announcement
21 March 2023

For Public Release

NZX Limited
Wellington

TruScreen Rights Offer closes
Results of the Rights Offer
TruScreen advises that it has closed its 1 for 5 pro rata renounceable rights offer ("Rights
Offer”), on 15 March 2023
The over subscription bookbuild price was set by the board at NZ$0.03 or A$0.029.
The Company raised a total of NZ$1.6m comprising;
Rights Offer
Approximately 33.7 million new shares being taken up by Eligible Shareholders from their
entitlements and over subscription applications, raising approximately NZ$1 million.
Placement
As previously announced to the market, TruScreen has also placed an additional 20 million
new ordinary fully paid shares at NZ$0.03 (raising NZD$600,000) in accordance with the 15%
Placement Rule.
Allotment of new shares
Settlement, allotment and trading in the new shares under the Rights Offer, and the Placement
is expected to occur on 22 March 2023 under the existing ticker “TRU”.
-ENDS-
This announcement has been approved by the Board.

Guy Robertson

Company Secretary

Ends
For more information, visit www.truscreen.com or contact:

Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetwork.com.au

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort, and the
need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for
devices marketed and sold in China.
TruScreen is currently targeting product sales to a range of low and middle-income countries,
including China, Mexico, Vietnam, Russia, Zimbabwe and Saudi Arabia, where no large-scale cervical
cancer screening programmes and infrastructure are currently in place. By doing so, the Company
hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/